Institutional Biosafety Committee

303-398-1436


The National Institutes of Health (NIH) requires that institutions establish an Institutional Biosafety Committee (IBC) to ensure that all recombinant DNA research be conducted in compliance with the NIH Guidelines for Research Involving Recombinant DNA Molecules. The IBC also reviews research protocols involving potential biohazards such as human, animal or plant pathogens; human materials (blood, cells, cell lines, tissues, body fluids, organs); and select agents (restricted human and animal pathogens and toxins that are considered by CDC to pose a potential threat to public health and safety).

 

Our Services

  • Processes, reviews and approves research protocols involving rDNA and other biohazards to ensure compliance with institutional, state and federal regulations

  • Assesses the facilities, procedures, practices, and training and expertise of personnel involved in research involving biohazards

  • Assists researchers to ensure that proper biosafety containment practices are used

  • Maintains institutional records of approved protocols and required reports to the NIH Office of Biosafety Activities

Featured Research

Genome Study Suggests New Strategies for Understanding and Treating Pulmonary Fibrosis

In findings published online in Nature Genetics on April 14, 2013, researchers at National Jewish Health, the University of Colorado and several other institutions found a number of genes associated with host defense, cell-cell adhesion and DNA repair, which provide clues to possible mechanisms underlying this currently untreatable disease. Read more.

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.